MX2014003325A - Vacunoterapia. - Google Patents

Vacunoterapia.

Info

Publication number
MX2014003325A
MX2014003325A MX2014003325A MX2014003325A MX2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A
Authority
MX
Mexico
Prior art keywords
amyloid
vaccine therapy
young
syndrome
protein
Prior art date
Application number
MX2014003325A
Other languages
English (en)
Other versions
MX350928B (es
Inventor
Andreas Muhs
Andrea Pfeiter
Rime Madani
William Charles Mobley
Pavel Vasilyevich Belichenko
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2014003325A publication Critical patent/MX2014003325A/es
Publication of MX350928B publication Critical patent/MX350928B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Abstract

La presente invención proporciona medios para tratar, aliviar y prevenir una patología relacionada con amiloideos en sujetos desde jóvenes hasta edad intermedia con síndrome de Down (DS). En particular, la presente invención proporciona fragmentos de péptido antigénico derivados de una proteína amiloidea o una proteína similar a amiloidea para el uso en el tratamiento preventivo de una patología relacionada con amiloideos en sujetos desde jóvenes hasta edad intermedia, con síndrome de Down.
MX2014003325A 2011-09-23 2012-09-21 Vacunoterapia. MX350928B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (2)

Publication Number Publication Date
MX2014003325A true MX2014003325A (es) 2014-05-21
MX350928B MX350928B (es) 2017-09-26

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003325A MX350928B (es) 2011-09-23 2012-09-21 Vacunoterapia.

Country Status (21)

Country Link
EP (1) EP2758071B1 (es)
JP (1) JP6110861B2 (es)
KR (3) KR20160099732A (es)
CN (2) CN109847058A (es)
AU (1) AU2012312126B2 (es)
BR (1) BR112014006871A2 (es)
CA (1) CA2811188C (es)
DK (1) DK2758071T3 (es)
EA (1) EA032494B1 (es)
ES (1) ES2712951T3 (es)
HU (1) HUE041277T2 (es)
IL (1) IL231564A0 (es)
MX (1) MX350928B (es)
MY (1) MY169574A (es)
PL (1) PL2758071T3 (es)
PT (1) PT2758071T (es)
SG (1) SG11201400795UA (es)
SI (1) SI2758071T1 (es)
TR (1) TR201901846T4 (es)
WO (1) WO2013044147A1 (es)
ZA (1) ZA201402071B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US20220226447A1 (en) 2019-05-21 2022-07-21 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1018883A4 (en) 1997-08-28 2001-05-16 Ajay North America PLANT AND CROP PROTECTION METHODS AND COMPOSITIONS
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2004209981B2 (en) * 2003-02-01 2009-02-26 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI379839B (en) * 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
NZ552480A (en) * 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
MY181173A (en) * 2005-12-12 2020-12-21 Ac Immune Sa Therapeutic vaccine
TWI453217B (zh) * 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體
SG174871A1 (en) * 2009-03-18 2011-11-28 Ac Immune Sa Method for therapeutic use

Also Published As

Publication number Publication date
ES2712951T3 (es) 2019-05-16
EP2758071A1 (en) 2014-07-30
PT2758071T (pt) 2019-01-11
HUE041277T2 (hu) 2019-05-28
WO2013044147A1 (en) 2013-03-28
SG11201400795UA (en) 2014-10-30
KR20160099732A (ko) 2016-08-22
IL231564A0 (en) 2014-04-30
KR102129220B1 (ko) 2020-07-02
EA201400376A1 (ru) 2014-09-30
PL2758071T3 (pl) 2019-08-30
CN104039346A (zh) 2014-09-10
KR20190035948A (ko) 2019-04-03
DK2758071T3 (en) 2019-02-18
CN109847058A (zh) 2019-06-07
BR112014006871A2 (pt) 2017-04-04
CA2811188C (en) 2020-04-28
JP2014531455A (ja) 2014-11-27
JP6110861B2 (ja) 2017-04-05
CA2811188A1 (en) 2013-03-23
AU2012312126B2 (en) 2016-11-10
AU2012312126A1 (en) 2014-03-27
KR20160005380A (ko) 2016-01-15
EA032494B1 (ru) 2019-06-28
MY169574A (en) 2019-04-22
NZ622653A (en) 2015-12-24
SI2758071T1 (sl) 2019-01-31
ZA201402071B (en) 2017-08-30
MX350928B (es) 2017-09-26
TR201901846T4 (tr) 2019-03-21
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MY179105A (en) Methods of treating alzheimer's disease
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
JO3591B1 (ar) مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
MY169574A (en) Vaccine therapy
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX2016001223A (es) Metodo para el pronostico de la eficacia de la inmunoterapia oral para el tratamiento de la alergia a las proteinas de leche de vaca.
GB201114923D0 (en) Immunogenic proteins and compositions

Legal Events

Date Code Title Description
FG Grant or registration